Is it time for some new approaches for treating advanced ovarian cancer?William P McGuire
J Natl Cancer Inst 98:1024-6. 2006
- Current aspects of adjuvant therapy of early stage ovarian cancer
W P McGuire
University of Mississippi School of Medicine, Atlanta, GA, USA
Zentralbl Gynakol 120:93-7. 1998
..More than two decades of studies are reviewed and conclusions offered. Additionally, important issues for the future therapy of this disease are presented...
- The Gynecologic Oncology Group experience in ovarian cancer
W P McGuire
University of Mississippi, Jackson, USA
Ann Oncol 10:29-34. 1999
....
- Current status of taxane and platinum-based chemotherapy in ovarian cancer
William P McGuire
Oncology Service Line, Franklin Square Hospital, Baltimore, MD 21237, USA
J Clin Oncol 21:133s-135s. 2003
..A separate article discusses the docetaxel-platinum doublet and how that might be considered an appropriate option for first-line therapy in patients with advanced, newly diagnosed ovarian cancer...
Primary ovarian cancer chemotherapy: current standards of careW P McGuire
Franklin Square Hospital Center, Baltimore, MD 21237, USA
Br J Cancer 89:S3-8. 2003
..g. docetaxel), other novel agents and new treatment schedules are ongoing...
- Contemporary management of ovarian cancer
D D Im
The Gynecologic Oncology Center, Mercy Medical Center, Baltimore, Maryland 21202, USA
Obstet Gynecol Clin North Am 28:759-73. 2001
..In the new millenium, new therapeutic modalities should enhance the current response rates...
- Clear cell carcinoma of the ovary: a remarkable case
J Giblin
The Emory Clinic, Atlanta, Georgia, USA
Am J Clin Oncol 24:99-100. 2001
..Treatment--and long-term maintenance therapy--with topotecan may be an option in such patients. In this case, the lack of cumulative toxicities allows the patient to maintain her usual daily activities...
- Recurrent ovarian cancer
Mohan K Tummala
Greenbaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
Clin Adv Hematol Oncol 3:723-36. 2005
..In this article we address these issues with an emphasis on evidence from the available literature and also discuss the clinical trials that are currently underway to resolve these issues...
- Liposomal anthracycline treatment for ovarian cancer
Maurie Markman
University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Semin Oncol 31:91-105. 2004
..Proper dosing and monitoring may further enhance tolerability while preserving the efficacy of this versatile agent for ovarian cancer...
- Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
William E Winter
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam
J Clin Oncol 25:3621-7. 2007
..The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC...
- Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group
David H Moore
Department of Obstetrics/Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA
J Clin Oncol 21:4207-13. 2003
..The questionnaire, referred to as the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity, may be used instead of VPT measurements in future studies of chemotherapy-induced peripheral neuropathy...
- Progress in the management of gynecologic cancer: consensus summary statement
Stephen A Cannistra
Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
J Clin Oncol 21:129s-132s. 2003
- Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study
William E Winter
Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA
J Clin Oncol 26:83-9. 2008
..To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC)...
- Ovarian cancer, CA-125 addiction, and informed confusion: much ado about less
Mohan K Tummala
J Clin Oncol 25:3570-1. 2007
- Ovarian cancer and the battle of the specialists
William P McGuire
J Clin Oncol 25:3554-5; author reply 3557-8. 2007
- A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer
Michael V Seiden
Gynecologic Oncology Research Program at Dana Farber Partners Cancer Care Program, Boston, MA 02115, USA
Gynecol Oncol 101:55-61. 2006
..To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy...
- CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?
William P McGuire
J Clin Oncol 23:5862-4. 2005
- Perioperative morbidity and the rush to chemotherapy
William P McGuire
J Clin Oncol 23:665-6. 2005
- Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks
Saroj Vadhan-Raj
Section of Cytokines and Targeted Therapies, Anderson Cancer Center, Houston, TX 77030, USA
J Support Oncol 1:131-8. 2003
....
- Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis
Barry Mirtsching
Center for Oncology Research and Treatment Dallas, Texas, USA
Oncology (Williston Park) 16:31-6. 2002
..In conclusion, darbepoetin alfa at a dose of 3.0 microg/kg given every 2 weeks safely increases hemoglobin concentration to the same extent as rHuEPO...
Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?Mohan K Tummala
Clinical Research Fellow, Clinical Research Branch, National Institute on Aging NIH and Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
Expert Rev Anticancer Ther 8:1135-47. 2008
....
